Arrowhead Pharmaceuticals CEO Makes a Multi-Million Dollar Stock Sale!

New insider activity at Arrowhead Pharmaceuticals ( (ARWR) ) has taken place on December 16, 2025.

CEO Christopher Richard Anzalone has made a significant move by selling 184,298 shares of Arrowhead Pharmaceuticals stock, amounting to a total value of $12,348,801.

Recent Updates on ARWR stock

Arrowhead Pharmaceuticals has recently experienced significant developments, notably the FDA approval of Rodemplo, marking its transition to a commercial-stage company. This approval, alongside robust financial performance with a reported revenue of $829 million for fiscal year 2025, underscores the company’s strategic growth. The earnings call highlighted strong strategic partnerships, including milestone payments from Sarepta and Novartis, and advancements in its pipeline programs. However, challenges remain, such as delays in obesity program timelines and regulatory uncertainties regarding pancreatitis risk reduction claims for Rodemplo. Despite these hurdles, Arrowhead’s diverse pipeline and strategic collaborations position it well for future growth, though market analysts have noted potential downside risks in stock price targets due to competitive pressures from generic drug approvals.

Spark’s Take on ARWR Stock

According to Spark, TipRanks’ AI Analyst, ARWR is a Neutral.

Arrowhead Pharmaceuticals’ overall stock score is driven by strong technical momentum and positive developments in its clinical pipeline and partnerships. However, significant financial challenges and valuation concerns weigh heavily on the score. The earnings call provided a cautiously optimistic outlook, but the company’s financial performance remains a critical area for improvement.

To see Spark’s full report on ARWR stock, click here.

More about Arrowhead Pharmaceuticals

YTD Price Performance: 248.35%

Average Trading Volume: 2,429,730

Technical Sentiment Signal: Buy

Current Market Cap: $9.52B